The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ABCL | +103.3% | N/A | N/A | -91% |
| S&P | +19.89% | +109.18% | +15.89% | +87% |
AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.
The Baker brothers are billionaires with a successful track record in the biopharmaceutical industry.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $17.08M | 133.3% |
| Gross Profit | $10.03M | 132.6% |
| Gross Margin | 58.68% | 478.1% |
| Market Cap | $1.02B | 17.6% |
| Market Cap / Employee | $1.72M | 0.0% |
| Employees | 596 | 1.7% |
| Net Income | -$34.73M | 6.0% |
| EBITDA | -$42.53M | 23.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $117.44M | -32.2% |
| Accounts Receivable | $47.31M | 30.9% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $137.18M | 106.4% |
| Short Term Debt | $4.90M | -12.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -11.77% | -1.4% |
| Return On Invested Capital | 2.84% | 0.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$47.01M | 4.6% |
| Operating Free Cash Flow | -$33.21M | -12.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.71 | 0.80 | 0.62 | 1.00 | 30.06% |
| Price to Sales | 23.26 | 30.05 | 28.72 | 31.14 | 18.21% |
| Price to Tangible Book Value | 0.78 | 0.88 | 0.68 | 1.10 | 21.45% |
| Enterprise Value to EBITDA | -3.07 | -4.74 | -1.81 | -13.82 | 209.43% |
| Return on Equity | -15.6% | -14.7% | -15.6% | -15.6% | 17.65% |
| Total Debt | $71.40M | $65.36M | $67.85M | $142.08M | 97.19% |
ABCL earnings call for the period ending December 31, 2024.
ABCL earnings call for the period ending September 30, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
